Equipoise 250 – Nakon Medical – US

$85.00

+ Free Shipping

Buy Equipoise 250 Injectable Steroid Online – Nexo Vira Lab

Active Half-Life: 14 Days
Classification: Anabolic Steroid
Dosage: Men 400–1000 mg/week
Acne: Rare
Water Retention: Low
Hepatotoxicity: Low
Aromatization: Low
Carrier Oil: MCT Oil
Manufacturer: Nakon Medical – US
Warehouse: USA Warehouse 5
Substance: Boldenone Undecylenate

Pricing

  • 1 Pack (10 ml x 250 mg/ml) – $85.00
  • 5 Pack (10 ml x 250 mg/ml) – $383.00 (Save $42.00)
  • 10 Pack (10 ml x 250 mg/ml) – $680.00 (Save $170.00)

Equipoise 250 (Boldenone Undecylenate)

Equipoise 250 is an injectable anabolic steroid containing Boldenone Undecylenate, known for promoting steady, high-quality muscle gains with minimal water retention. It is widely used for improving endurance, appetite, and overall performance.

Effects

  • Lean and quality muscle growth
  • Increased appetite
  • Enhanced vascularity
  • Improved strength and endurance
  • Better oxygen transport in the body
  • Low androgenic activity
  • Minimal water retention

Possible Side Effects

Although generally considered mild compared to other anabolic steroids, potential side effects may include:

  • Acne
  • Increased blood pressure
  • Prostate enlargement (in sensitive individuals)

These risks can be reduced with proper monitoring and responsible use.

Cycle Information

Beginner / Intermediate Cycle:

  • 600–800 mg per week for 8 weeks

Advanced Cycle Options:

  • Equipoise 250 + oral compounds (e.g., Turanabol)
  • Equipoise 250 + Trenbolone (experienced users only)

Cycle combinations should be carefully planned to minimize risks and optimize results.

Important Notes

  • May suppress natural testosterone production
  • Post Cycle Therapy (PCT) is recommended after use
  • Not suitable for women due to androgenic effects

Warnings

  • Keep out of reach of children
  • For adult use only

 

Reviews

There are no reviews yet.

Be the first to review “Equipoise 250 – Nakon Medical – US”

Your email address will not be published. Required fields are marked *